Abstract
AbstractThe success of medical treatment for the management of glaucoma depends largely on patients' compliance with the treatment regimen. Ophthalmic topical beta blockers have had a significant impact on the medical management of glaucoma by providing effective ocular hypotensive action coupled with improved patient compliance, which has been achieved by reduced frequency of instillation of the eye drops and minimal side effects.This paper reviews the wide range of ocular and systemic adverse effects associated with the use of ophthalmic beta blockers and highlights the specific population groups at increased risk for these reactions. Clinicians may, however, continue to take advantage of the promise shown by beta blockers to reduce intraocular pressure with minimal adverse reactions by their selective use in patients with glaucoma. Other precautionary measures to minimize the frequency and severity of systemic adverse effects related to topical beta blockade are discussed. Many of the newer ophthalmic ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Toxicology: Cutaneous and Ocular Toxicology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.